Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The “Finer Points”
Open Access
- 24 October 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (1), 1-3
- https://doi.org/10.1002/onco.13572
Abstract
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.Keywords
This publication has 16 references indexed in Scilit:
- Estimation of Kidney Function in OncologyClinical Journal of the American Society of Nephrology, 2019
- Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective studyBreast Cancer Research and Treatment, 2017
- Ovarian cancer in the older womanJournal of Geriatric Oncology, 2016
- Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerThe New England Journal of Medicine, 2016
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trialThe Lancet Oncology, 2015
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trialThe Lancet Oncology, 2013
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2009
- Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinomaGynecologic Oncology, 2009
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003